Celltrion has secured marketing authorisation from the EC for Avtozma, a biosimilar to Chugai Pharmaceutical’s RoActemra ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Celltrion's Avtozma, a biosimilar to Actemra, was approved by the European Commission for sale in member states.

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Credit: Celltrion Avtozma, formerly known as CT-P47, is an interleukin-6 receptor antagonist. Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity ...

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European ...